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Abstract
Bladder cancer occurs in the majority of cases in males. It represents the seventh most common cancer and the
ninth most common cause of cancer deaths for men. Transitional cell carcinoma is the most predominant
histological type. Bladder cancer is highly chemosensitive. In metastatic setting, chemotherapy based on cisplatin
should be considered as standard treatment of choice for patients with good performance status (0-1) and good
renal function-glomerular filtration rate (GFR) > 60 mL/min. The standard treatment is based on cisplatin
chemotherapy regimens type MVAC, HD-MVAC, gemcitabine plus cisplatin (GC) or dose dense GC. In unfit patients,
carboplatin based regimes; gemcitabine plus carboplatin or methotrexate plus carboplatin plus vinblastine (MCAVI)
are reasonable options. The role of targeted therapies when used alone, or in combination with chemotherapy, or in
maintenance, was evaluated; targeting angiogenesis seem to be very promising. The purpose of this literature review
is to highlight the role of chemotherapy in the management of advanced transitional cell carcinoma of the bladder.
1- Introduction
The incidence of bladder cancer is increasing. An esti-
mated 386,300 new cases and 150,200 deaths from blad-
der cancer occurred in 2008 worldwide [1]. The highest
incidence is observed in Egypt with 37 cases per 100,000
inhabitants [2]. Bladder cancer occurs in the majority of
cases in males with a male/female sex ratio of 3:1. It
represents the seventh most common cancer for men [1].
In France, 10 700 new cases were diagnosed in 2000 and
accounts for 3.5% of all cancer deaths. Bladder cancer is
the sixth most common cancer (fifth most common can-
cer in men and seventh in women). In Morocco, bladder
cancer was the sixth most common cancer in 2005
according to Rabat registry. The average age of diagnosis
is 65 years [3].
Smoking is the most implicated risk factor in western
countries, followed by other factors such as polycyclic
aromatic hydrocarbons and cyclophosphamide [2]. In East
Africa (especially Egypt), chronic infection with Schisto-
soma haematobium is the most common etiology and is
often associated with squamous cell carcinoma [1,2].
Transitional cell carcinoma (TCC) is the most predo-
minant histological type which represents more than
90% of the cases [4,5].
In more than 70% of the cases, the diagnosis is made at
early stage of the disease (stages Ta and T1). Fifty percent
of the patients with the disease at advanced stages (T2 or
more) experience metastatic relapse.
In metastatic setting, chemotherapy treatment remains
the only therapeutic option. It has the objective to alleviate
the symptoms, to improve quality of life and to improve
survival. In bladder TCC, chemotherapy showed very little
progress and the standard MVAC is still the most used
regimen and that since several years. New drugs are in the
process of development, including those used in targeted
therapies for which the role remains to be defined more
clearly. This review emphasizes the role of chemotherapy
and targeted therapies in metastatic bladder transitional
cell carcinoma. Neoadjuvant or adjuvant chemotherapy,
and systemic treatment of other histological types such as
squamous cell carcinoma, adenocarcinoma, lymphoma,
sarcoma and small cell carcinoma are not discussed in this
article [4,5].
2- Methods of research
The literature review was conducted by using PUBMED
data base using the following keywords: bladder cancer,
transitional cell carcinoma, chemotherapy, cisplatin, and
targeted therapies. The abstracts of papers presented at
the annual meeting of the American Society of Medical
Oncology (ASCO) were also analyzed. All Phase III trials
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been also included in our article. The research was carried
out from January 1980 until July 2011.
3- Prognostic factors in metastatic setting
Performance status (> 0), hemoglobin level (< 10 g/L), and
liver metastasis are recognized as independent factors of
poor prognosis in metastatic setting according to a recent
prospective study. The median overall survival (OS) of 370
patients treated with chemotherapy for TCC carcinoma of
the bladder with 0, 1, 2 and 3 factors were 14.2, 7.3, 3.8,
and 1.7 months (P < 0.001), respectively [6].
Prognostic factors helps better to define the therapeu-
tic strategy. For patients with 2 or 3 factors, it is sug-
gested that aggressive chemotherapy should be avoided
because of an increased risk of toxicity [6].
4- Chemotherapy in metastatic disease
4.1- Single agents
Bladder TCC are chemosensitive tumors. However, the
response to a single agent is limited. Cisplatin is one of the
most active drugs that give the highest overall response
rate (ORR). Other drugs are also active (Table 1).
4.2- Multi agents chemotherapy
4.2.1- Cisplatin-based chemotherapy
4.2.1.1- Conventional regimens The first protocols
based on cisplatin (CMV: cisplatin, cyclophosphamide
and vinblastine; and CISCA: cisplatin, doxorubicin and
cyclophosphamide) induced 12 to78% ORR. The two
protocols CMV and CISCA were widely used in the
1980s but did not show superiority in survival versus
cisplatin alone [7-10].
Since 1990, the MVAC has been considered as a stan-
dard first-line therapy in metastatic disease. This regimen
was for the first time studied in a nonrandomized phase II
trial by Sternberg and colleagues in 1985 [11,12] and
concerned 25 patients. They showed a sustained ORR in
71% of the cases and 50% of complete responses (CR).
Two randomized phase III trials demonstrated the super-
iority of the MVAC to CISCA and CDDP, respectively,
both in ORR, and in OS [13,14]. The MVAC is efficient,
but particularly toxic. In the phase II study [11], the com-
bination induced one toxic death and 4 febril neutropenias
(16%), in addition to vomiting, anorexia, mucositis (grade
3-4 in 22% of the cases), alopecia and renal insufficiency.
To improve the results obtained with the MVAC, an
intensification of this same protocol as HD-MVAC was
tested in a phase III EORTC trial including more than 250
patients. In the experimental arm, all drugs were adminis-
tered in day 1 and day 14. Prevention of toxicity was based
on the routine use of Granulocyte Colony-Stimulating
Factors (GCSF). Although the OS which represents the
primary end point of the study, was identical in the two
arms at 7.3 years median follow-up. However, the study
showed that the intensification of the protocol improved
CR (25 vs. 10%) and progression-free survival (PFS)
(9.5 vs. 8.1 months, p = 0.03). Survivals at 2 and 5 years
were also better (37% -22% vs. 25-22%, respectively). In
addition, the systematic use of GCSF made the HD-
MVAC better tolerated. While the primary end point was
not achieved, the intensified MVAC is widely used in
metastatic settings [15,16].
Table 2 summarizes the results of the most important
phase III trials investigating first line chemotherapy in
advanced bladder TCC.
4.2.1.2- Second generation drugs
* Gemcitabine based regimens
In the 1990s, gemcitabine was a new molecule in the
treatment of bladder TCC.
The first phase II trials evaluating the use of gemcita-
bine as single agent showed an improvement of ORR by
24 to 28%. The combination of gemcitabine with cisplatin
(GC) has further improved these results with higher ORR
(57%) and CR (15 to 21%) [17].
Based on these encouraging results, a phase III trial
was conducted to compare the GC protocol to the stan-
dard MVAC. The study was designed to demonstrate
superiority of the experimental arm in OS. The results
showed no improvement of OS (MVAC: 14.8 months
vs. GC: 13.8 months) and ORR (MVAC: 45.7 vs. GC:
49.4%). But due to the better safety profile, the GC was
considered not inferior to MVAC [18,19].
A recent phase III trial compared the intensified HD-
MVAC (n = 118) to the dense dose GC (DD-GC) (n =
57) (G: 2500 mg/m
2, C: 70 mg/m
2 q 2 wks). The results
were presented this year at the ASCO 2011 and showed
that efficacy was similar in both treatments (ORR = 47.4
vs. 47.4%, respectively: p = 0.9; and OS = 18.4 vs. 20.7
months, respectively: p = 0.7), however, the safety profile
was slightly better in favor to DD-GC [20].
Table 1 ORR of single agents
Drogues ORR
Cisplatin 33%
Methotrexate 29%
Doxorubicin 23%
5-fluoro-uracil 35%
Vinblastine -
Cyclophosphamide -
Mitomycine C 21%
Carboplatin 12-14%
Gemcitabine 24-28%
Paclitaxel 10-40%
Docetaxel 13-31%
Vinflunine 15%
Eribulin 38%
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Cisplatin was also tested in phase II studies with other
new drugs, particularly with taxanes (Table 3). The
combination of cisplatin with paclitaxel and cisplatin
with docetaxel improved ORR by 50-70% and 52-62%
respectively [21-25].
We note that these combinations remain inferior to
the standard chemotherapy as was proven by the phase
III randomized study conducted by the Hellenic Coop-
erative Oncology Group comparing docetaxel-cisplatin
to MVAC. The standard protocol was superior in ORR
(54.2% vs. 37.4%, p = 0.017), time to progression (TTP)
(9.4 vs. 6.1 months, p = 0.003) and OS (14.2 vs. 9.3
months, p = 0.026) [26].
4.2.2- Chemotherapy doublets based on other platinum
drugs
Carboplatin is not as efficient as cisplatin. But has the
advantage of being easily administered and better toler-
ated. Therefore, carboplatin-based protocols should be
considered in patient ineligible (unfit) for cisplatin-based
chemotherapy (Table 4) [27].
Carboplatin has been tested with paclitaxel in several
phase II trials and permitted to achieve more than 63%
ORR, but CR was limited as compared to cisplatin based
protocols. Based on these frustrating results and other
data suggesting the limited activity of this protocol
[29,30], a phase III study was stopped early due to lack of
recruitment. This study was designed to compare pacli-
taxel-carboplatin to MVAC [31].
Gemcitabine used in combination with carboplatin
showed significantly lower results than cisplatin plus
gemcitabine. ORR was high (59%), but the comparison
with the GC showed that the standard arm was signifi-
cantly better according to the results of one randomized
phase II study [32-35].
Oxaliplatin is another platinum drug which showed
only marginal activity as monotherapy [36].
In another hand, the EORTC conducted a phase III
trial comparing unfit patients having metastatic TCC, the
protocol based on carboplatin (AUC 4.5 on day) - gemci-
tabine (1000 mg/m
2 on day 1 and day 8) (GCa), repeated
every 21 days, to the protocol M-CAVI [methotrexate
(30 mg/m
2 o nd a y1 ,d a y1 5 ,a n dd a y2 2 ) ,c a r b o p l a t i n
(AUC 4.5 on day 1) and vinblastine (3 mg/m
2 on day 1,
Table 2 Randomized phase III trials investigating first-line chemotherapy regimens in metastatic bladder TCC
Authors Journal
or
meeting
Year Treatments No Results Toxicity
Logothetis [13] JCO 1990 MVAC vs.
CISCA
120 Sup: ORR = 65 vs. 46%, p < 0.05,
and OS = 62.6 vs. 48.3 weeks
Sup
Loehrer [14] JCO 1992 MVAC vs.
Cisplatin
146 Sup: ORR = 39 vs. 12%, p < 0.0001;
PFS = 10 vs. 4.3 months, and OS =
12.5 vs. 8.2 months
Sup
Von der Maase [18,19] JCO 2000 MVAC vs.
GC
405 Equivalents more neutropenic sepsis (12% vs. 1%; P < 0.001)
and more grade 3-4 mucositis (22% vs. 1%; P =
0.001) on the MVAC arm
Sternberg [15,16] JCO 2001 HD-MVAC
vs. MVAC
259 Equivalents less neutropenic fever (10% vs. 26%; P < 0.001)
and mucositis on the HD-MVAC arm
Bamias [26] JCO 2004 MVAC vs.
DC
120 Sup
Dreicer [31] Cancer 2004 MVAC vs.
PCa
85 Interrupted early Sup
Bellmunt [48] ASCO 2007 PCG vs. GC 627 Equivalents Sup
De Santis [37] ASCO 2010 GCa vs.
MCAVI
238 Equivalents Inf
Bamias [20] ASCO 2011 DD-GC vs.
HD-MVAC
175 Equivalents Inf
Abbreviations. JCO: Journal of Clinical Oncology; MVAC: methotrexate-vinblastine-doxorubicin-cisplatin; CISCA: cisplatin-cyclophosphamide-doxorubicin; DC:
docetaxel plus cisplatin; PCG: paclitaxel-cisplatin-gemcitabin; PCa: paclitaxel plus carboplatin; MCAVI: methotrexate-carboplatin-vinblastine; HD: high dose; DD:
dose dense; ORR: objective response rate; OS: overall survival; PFS: progression free survival. Sup = superior; Inf = inferior.
Table 3 Phases II trials evaluating taxanes based
doublets
Authors Treatments N Results
Burch et al [21] PC 34 ORR = 70%
Dreicer et al [22] PC 52 ORR = 50%
OS = 10.6 months
Dimopoulos et al [23] DC 66 ORR = 52%
TTP = 5 months
OS = 8 months
DelMuro et al [24] DC 38 ORR = 58%
TTP = 6.9 months
OS = 10.4 months.
Sengelov et al [25] DC 25 ORR = 60%
OS = 13.6 months
Abbreviations. PC: paclitaxel-cisplatin; DC: docetaxel-cisplatin; ORR: overall
response rate; OS: overall survival; TTP: time to progression.
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presented at ASCO 2010, confirmed the equivalence in
OS between the 2 treatments, with a better toxicity pro-
file in favor to the GCa protocol [37].
4.2.3- Doublets without platinum drugs
Data on the effectiveness of drugs, in patients with good or
poor condition are not sufficient. The literature reports
only phase II trials with low number of patients. The pro-
tocol which is most studied is based on gemcitabine in
combination with other molecules.
Gemcitabine-paclitaxel combination appears to produce
a significant improvement. This protocol improved ORR
to 40-60% [38-40]. Several schemes were tested. A phase
II study investigated the gemcitabine-paclitaxel weekly,
showed an ORR of up to 69% (42% of CR), however the
r a t eo fg r a d e3 - 4p u l m o n a r yt o x i c i t ya n dt o x i cd e a t hi s
high. Therefore, the authors recommended disregard the
use of this regimen in practice [41].
With docetaxel, gemcitabinei sa c t i v ea n dw e l lt o l e r -
ated. In 3 different phase II studies the ORR was between
30 and 50% [42-44].
Gemcitabine was also evaluated in association with
pemetrexed in 2 phases II trials in 64 and 44 patients,
respectively. The ORR was 20 and 28%. But this combi-
nation was very hematotoxic. In addition, 2 toxic deaths
were reported [45,46].
4.2.4- Triplets
To improve the ORR, several phase II and III studies
were conducted by testing the addition of a third drug
to the standard protocols used in practice.
Paclitaxel, in combination with GC, was the first triplet
studied in a phase II trial conducted by Bellmunt, show-
ing 77.6% ORR in 58 patients (ORR = 27.6% and PR =
50%) [47]. Therefore, the authors concluded the feasibil-
ity and the activity of this triple association. This was the
background of a phase III randomized trial developed by
the EORTC group, comparing the same protocol to the
standard protocol GC. The authors considered the OS as
ap r i m a r ye n d p o i n t .E v e nw i t h significant superiority in
ORR for the experimental arm (57.1 vs. 46.4%, p = 0.02),
the primary objective of the study was not achieved
(OS = 15.7 vs. 12.8 months, p = 0.12, PFS = 8.4 vs. 7.7
months, p = 0.01) [48].
Bajorin has evaluated the feasibility and safety of pacli-
taxel, ifosfamide and cisplatin triplet administered every
3 weeks in a phase II study. Among 44 evaluable
patients, the rate of CR was 23% and PR was 45%. The
median survival was 20 months [49].
Paclitaxel-carboplatin-gemcitabine triplet was investi-
gated in two phase II trials involving patients in the first
line in one trial, and in 1st/2nd lines in another trial. ORRs
and CR were equal to 43-68%, and 32-12%, respectively.
The OS was equal to 14.7 and 11 months, respectively
[50,51].
Other combinations including paclitaxel have also
been reported in the literature, and showed promising
activity and acceptable toxicity profile, but, more investi-
gations are required in clinical trials [52-54].
The cisplatin-epirubicin-docetaxel triplet gave 30% com-
plete responses in first line in 30 evaluable patients. The
ORR was 66.7%. The median survival reached 14.5
months. Even for patients with PS 3, the overall safety pro-
file was comparable to MVAC [55].
4.2.5- Sequential protocols
Based on the effectiveness of the sequential regimens in
breast cancer, this option was studied in metastatic
bladder cancer.
In a phase II trial, the doublet doxorubicin-gemcitabine
was evaluated in sequence with the triplet paclitaxel-ifosfa-
mide-cisplatin in previously untreated patients (n = 60)
with advanced TCC, with the systematic use of GCSF. In
the final results recently published, the authors conclude
that the regimen is active; however, it is associated with
high rate of grade 3-4 hematological toxicity and does not
clearly offer a benefit compared with the standard treat-
ments [56]. In another trial, 25 patients with advanced
urothelial carcinoma who were ineligible for cisplatin,
received doses-dense sequential treatment with doxorubicin
plus gemcitabine followed by paclitaxel plus carboplatin.
ORR was 56% and the treatment was well tolerated [57].
Table 5 summarizes the most important prospective stu-
dies evaluating the role of triplet and sequential regimens.
Table 4 Phases II trials evaluating carboplatin based doublets
Auteur Treatment No Results
Redman et al [28] PCa 35 ORR = 51%; OS = 9.5 months
Small et al [29] PCa 29 ORR = 20,7%; TTP = 4 months; OS = 9 months
Vaughn et al [30] PCa 33 ORR = 50%
Bellmunt et al [32] GCa 16 ORR = 44%
Nogue-Aliguer et al [33] GCa 41 ORR = 56.1%; PFS = 7.2 months; OS = 10.1 months
Shannon et al [34] GCa 17 ORR = 58.8%; PFS = 4.6 months; OS = 10.5 mois
Dogliotti et al [35] GCa vs. GC (Randomized phase II) 110 Efficacy: CR: 1.8% vs. 14.5%; OS: 9.8 vs. 12.8 months
Toxicity: Equivalent.
Abbreviations. PCa: paclitaxel-carboplatin; GCa: gemcitabine-carboplatin; GC: gemcitabine-cisplatin; ORR: objective response rate; OS: overall survival; PFS:
progression free survival.
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After failure of cisplatin-based first-line therapy, there
was no consensus in the management of cisplatin resis-
tant disease.
Taxanes (paclitaxel and docetaxel), vinflunine, and
antifolate compounds (trimetrexate, piritrexim, and
pemetrexed) resulted in 7 to 23% ORR. The FOLFOX4
was also studied in a phase II trial and resulted in 19%
ORR [58-60]. In a recent published case study, the
authors obtained a CR with FOLFOX4 chemotherapy in
a metastatic urothelial cancer patient, after failure of GC
combination [61].
The first phase III trial on cisplatin refractory setting
compared vinflunine to best supportive care. Vinflunine is
a semi-synthetic, vinca alkaloid compound that targets the
microtubules. It was used at a dose of 320 mg/m
2 repeated
every 21 days until progression or intolerance. Compared
with the control arm, vinflunine was superior in OS > 2
months, however significant grade 3-4 hematologic toxici-
ties (6% of febril neutropenia, one toxic death, anemia,
and thrombocytopenia) were noted [62].
The second phase III trial was designed to compare a
short-term (six cycles: arm A) versus prolonged (until pro-
gression: arm B) second-line combination chemotherapy
of gepcitabine-paclitaxel. On prolonged treatment, more
patients experienced severe anemia (arm A: 6.7% versus
arm B: 26.7% grade 3-4 anemia; P = 0.011). Therefore, the
authors concluded that it was not feasible to deliver a pro-
longed regimen. However, a high response rate of 40%
makes the short protocol (6 cycles) a promising second
line treatment option for patients with metastatic TCC
[63].
4.4- New molecule
Eribulin is a new agent targeting the microtubules, being
tested in several primary tumors. In advanced or meta-
static TCC, this molecule was evaluated in a phase II trial,
and showed a very interesting antitumor activity in front
line with 38% ORR. The PFS was estimated to 3.9 months
and the safety profile was acceptable (neutropenia, neuro-
pathy, hypoglycemia, and hyponatremia) [64]. Based on
these results, a phase III trial is undergoing to compare
the standard GC to the combination of GC to Eribulin.
4.5- Targeted therapies
Despite the promising results obtained by chemotherapy
based on MVAC or GC, the majority of patients die of
metastatic disease.
The new progress in molecular biology has prompted
the investigators to evaluate several molecules in meta-
static bladder TCC.
Overexpression of several receptors such as the
VEGFR (vascular endothelial growth factor receptor) on
endothelial cells, the EGFR (epidermal growth factor
receptor, the PDGFR (platlet derived growth factor
receptor), and the FGFR (fibroblast growth factor recep-
tor), on tumor cells, led the investigators to evaluate the
efficacy and safety of new molecules targeting signaling
pathways controlled by these proteins in metastatic
setting (Figure 1).
Table 5 Phases I/II trials evaluated the triplets and sequential regimens
Authors Treatments Trial
phase
No Efficacy Toxicity
Bellmunt et al [47] CPG I/II 58 ORR = 77.6%; CR = 27.6%; PR = 50%;
OS = 24 months.
Hematological+++ (Grade 3/4 neutropenia and
thrombocytopenia in 55% and 22%, respectively)
Bajorin et al [49] ITP II 44 CR = 23%.; PR = 45%.; OS = 20 months. Well tolerated
Hussain et al [50] CaPG II 49 CR = 32%; PR = 36%; OS = 14.7
months; 1 years survival = 59%
Hematological+++
Hainsworth et al [51] CaPG II 60 (7% in
2nd line)
ORR = 43%; CR = 12%; OS = 11
months;
Hematological+++ (10% of febril neutropenia)
One toxic death
Edelman et al [52] M-CaP
(GCSF)
I/II 33 ORR = 56%; OS = 15.5 months. Hematological and neuropathy
Tu et al [53] M-CP II 25 (2
nd
line)
PR = 40%; CR = 0% Acceptable
Law et al [54] M-GP II 20 ORR = 45% (CR = 6; PR = 3); OS = 18
months; PFS = 6.3 months
Neutropenia+++ (1 toxic death)
Pectasides et al [55] EDC II 30 ORR = 66.7% (CR = 30%; PR = 36.7%);
OS = 14.5 months.
Hematological (4 episodes of febril neutropenia)
Milowsky MI et al
[56]
AG ® ITP
with GCSF
II 60 ORR = 73% (CR = 35% and PR = 38%);
PFS = 12.1 months; OS = 16.4 months
Myelosupression (grade 3-4): 68%
Febril neutropenia (25%)
Galsky MD et al [57] AG ® ITCa
with GCSF
I/II 21 ORR = 56% (CR = 5; RP = 9) Myelosupression (grade 3-4): 28%
Febril neutropenia: 8%
Abbreviations. ITP: ifosfamide-paclitaxel-cisplatin; CPG: cisplatin-paclitaxel-gemcitabine; CaPG: carboplatin-paclitaxel-gemcitabine; M-CaP: methotrexate-
carboplatin-paclitaxel; M-CP: methotexate-cisplatin-paclitaxel; M-GP: methotrexate-gemcitabine-paclitaxel; EDC: epirubicin-docetaxel-cisplatin; AG: doxorubicin-
cisplatin; ITCa: ifosfamide-paclitaxel-carboplatin; CR: complete response; PR: partial response; ORR: objective response rate; OS: overall survival; PFS: progression
free survival.
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with chemotherapy, and in maintenance was evaluated
using different molecules (bevacizumab, sunitinib, sora-
fenib, pazopanib, dovitinib, vandetanib, trastuzumab,
cetuximab, erlotinib, lapatinib, everolimus, bortezomibe)
(Table 6) [65-84].
4.5.1- Targeting angiogenesis
Increased signaling through VEGFR and FGFR charac-
terizes many TCC tumors and increased tumor vasculari-
zation. Angiogenesis is a very important step to tumor
g r o w t h ,i n v a s i o na n dm e t a s t a s i s .T h e r e f o r e ,t a r g e t i n g
angiogenesis is a very interesting strategy which can be
achieved by the use of monoclonal antibodies or by using
small molecules tyrosine kinase inhibitors.
(A) Monoclonal antibodies
*Bevacizumab
Bevacizumab is a humanized monoclonal antibody
(mAb) targeting the VEGF (Vascular Endothelial Factor)
which has been approved by FDA in combination with
chemotherapy as a standard treatment in first line and
second line in different metastatic tumors. In bladder
TCC, bevacizumab (15 mg/kg on day 1) was evaluated in
first line treatment in combination with GC protocol
(gemcitabine 1250 on D1 and D8 and cisplatin 70 mg/m
2
on D1, the cycle was repeated every 21 days) in a phase II
trial (45 patients). Mature data presented at ASCO 2010
showed similar results in ORR and PFS to those obtained
by the GC protocol, but OS was superior estimated to
20.4 months. A phase III trial comparing GC to GC plus
bevacizumab is undergoing [66].
(B) Small molecules
*SU11248 Sunitinib Sutent
®
Sunitinib is a small molecule playing as a multi target
intracellular tyrosine kinases inhibitor by inhibiting multi-
ple receptors (EGFR, VERFR-1/2, C-KIT, PDGFR a/b)
and the FLT3 and RET kinases. This drug has been
approved by the FDA in the front line treatment of meta-
static renal cell carcinoma and in the second line treat-
ment of GIST (gastrointestinal stromal tumors) after
failure of imatinib. Sunitinib has been tested in bladder
cancer as single agent, in combination with chemotherapy,
and in maintenance, and showed an interesting anti-
tumor activity [67-71]. In a phase II trial presented at
ASCO 2010, the Sunitinib was evaluated in association
Figure 1 Deregulated signaling pathways and targeted therapy in bladder cancer. Abbreviations: EGFR, Epithelial Growth Factor
Receptor; VEGFR, Vascular Endothelial Growth Factor R; FGFR: Fibroblast Growth Factor Receptor; mTOR: mammalian Target of Rapamycin.
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of hematological toxicity [70]. In another phase II study
also presented at ASCO 2010, including 33 unfit patients
treated with single agent sunitinib, the TTP was estimated
to 4.8 months and the clinical benefit to 67%, confirming
the role of the angiogenic pathway as an interesting target
in the treatment of bladder TCC [71].
*BAY43-9006 Sorafenib Nexavar
®
Sorafenib is another small multi-target molecule (B-Raf,
c-Raf, VEGFR-2/3, VEGFR-3, PDGFR-b) which has been
approved by the FDA in second line treatment of meta-
static renal cell carcinoma after failure of immunotherapy,
and in first line treatment of advanced hepatocellular carci-
noma, Child A. It has been tested in bladder TCC as single
agent and in combination with chemotherapy in first and
second line metastatic disease. However, Sorafenib didn’t
have activity in monotherapy [72], and in the combination
with GC. Sorafenib did not improve the results of the stan-
dard GC in a recent randomized phase II trial [73].
*TKI258 Dovitinib
Dovitinib is an oral drug that inhibits angiogenic factors,
including the FGFR and the VEGFR. TKI258, adminis-
tered at a dose of 500 mg/day taken 5 days per week dos-
ing schedule, was evaluated in phase II trial in second line
treatment. The results of this trial, presented this year at
the ASCO 2011, are promising [74].
4.5.2- EGFR inhibitors
(A) Monoclonal antibodies
* Trastuzumab
The amplification of the HER2/neu oncogene has been
correlated in bladder cancer to a more aggressive disease
[75]. Bladder tumors with HER2 amplification represent
10-50% of cases [76-78].
In a multicenter U.S. Phase II study, trastuzumab was
tested in combination with paclitaxel-carboplatin-gemci-
tabine triplet. The study included 109 patients, 57 (52%)
had HER2 amplification, and 54 of 57 patients were trea-
ted with trastuzumab. The main toxicities were hemato-
logical, neurological and cardiac. ORR rate was equal to
70%. The TTP was 9.3 months and OS was14.1 months
[79].
(B) Small molecules
* Gefetinib ZD1839 IRESSA
®
Gefitinib is a small molecule tyrosine kinase inhibitor
that has been recently approved by the FDA in the front
line treatment of metastatic non small cell lung cancer
with activated EGFR mutation. In bladder cancer, it was
in the first time evaluated as monotherapy in second-line
therapy. This study showed no ORR. Median PFS was
limited [80]. Gefitinib was also studied with GC in first
line treatment. The results were similar to the GC and
MVAC (CALGB 90102) [81].
* GW 572016 Lapatinib Tykerb
®
Lapatinib is a small molecule tyrosine kinase inhinitor
allowing the inhibition of HER1 and HER2 receptors. This
molecule has been approved by the FDA in the treatment
of metastatic breast cancer with HER2 amplification. In
one study, 59 patients with HER2 and/or EGFR amplifica-
tions were treated after failure of one or more therapeutic
lines. In this phase 2 trial, only one patient (3%) had a par-
tial response and 4 (12%) had stable disease [82].
4.5.3- mTOR inhibitors
The mammalian target of rapamycin (mTOR) is an intra-
cellular serine/threonine protein kinase positioned at a
central point in a variety of cellular signaling cascades.
The established involvement of mTOR activity in the
Table 6 Phase II trials evaluating the role of targeted therapies
Organisations Treatments Trial
phase
Line No Results Most common grades 3-4
toxicities
Hoosier Oncology
Group [66]
GC +
Bevacizumab
II 1st 43 ORR = 72% (21% de; CR et 51% de RP); PFS = 8.2
months; OS = 20.4 months
Hematological,
thromboembolism
USA (Texas) [70] GC +
sunutinib
II 1st 15 Interrupted for toxicity Hematological++
Espagne [71] Sunitinib II 1st 37 DC = 8%; PFS = 5.9 months Fatigue, Hypertention,
Hand-Foot syndrom
Allemagne [73] GC +
sorafenib
IIR 1st 85 ORR = 82% vs. 78%; PFS = 6.3 mois vs. 7.2 months Hematological
NCI Trial [79] Trastuzumab
+ CaPG
II 1st 44
(HER2++
+)
ORR = 70% (11% de CR et 59% de RP); OS = 14
months
Hematological, sensory
neuropaty, cardiac
CALGB [81] Gefitinib +
GC
II 1st 58 ORR = 48%,; PFS = 7 months,; OS = 15 months;
Equivalents results to GC et MVAC
Hematological, skin rash,
diarrhea,
Allemagne [82] Lapatinib II 2nd and
more
59 PR = 3%; S = 12%; PFS = 8.6 weeks Diarrhea, vomiting,
dehydration
Italy and USA [84] Everolimus II 2nd 45 PR = 8%; PFS = 3.3 months; OS = 10.5 months Hematological, fatigue,
metabolic, mucositis
Abbreviations. GC: gemcitabine-cisplatin; ORR: objective response rate; RC: complate response; PR: partial response; S: stabilisation; DC: disease control; PFS:
progression free survival; OS: overall survival; CaPG: paclitaxel-gemcitabine-carboplatin.
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progression of cancer has identified mTOR as a major link
in tumorigenesis. Consequently, inhibitors of mTOR, have
been developed and assessed for their safety and efficacy
in patients with cancer [83].
* Everolimus RAD001 AFINITOR
® Everolimus is an
oral rapamycin compound targeting and inhibiting the
PI3K/Akt/mTOR pathway a central regulator of cell
growth, proliferation, survival, and angiogenesis. It is
currently indicated in second line treatment of meta-
static renal cancer after failure of one tyrosine kinase
i n h i b i t o r .T h eR A D 0 0 1w a st e s t e da tad o s eo f1 0m g
daily in 2 phase II trials in second line treatment. The
results of these 2 trials were presented this year at
ASCO 2011 and showed limited activity of Everolimus
(PR = 8%; PFS = 3.3 months; OS = 10.5 months, in one
study) [84].
4.5.4- Histone deacetylase inhibitors
Histone deacetylases (HDACs) can regulate expression of
tumor suppressor genes and activities of transcriptional
factors involved in both cancer initiation and progression
through alteration of either DNA or the structural compo-
nents of chromatin. Recently, the role of gene repression
through modulation such as acetylation in cancer patients
has been clinically validated with several inhibitors of
HDACs. In bladder cancer, Belinostat (PXD101) a HDACs
inhibitor, was shown to be active according to several pre-
clinical studies [85,86].
5- Treatment recommandations (Table 7)
(A) First line treatment
In metastatic setting, chemotherapy based on cisplatin
should be considered as standard treatment of choice for
patients with good performance status (0-1) and good
renal function-Glomerular filtration rate (GFR) > 60 mL/
min. MVAC, HD-MVAC, gemcitabine-cisplatin and dose-
dense gemcitabine-cisplatin should be considered as four
standard first-line chemotherapy treatments for metastatic
bladder TCC.
Taxane-based doublets are inferior to the standard
MVAC and should not be used in first-line.
Carboplatin-based combinations are inferior to cispla-
tin based regimens and should be only used in unfit
patients.
The platinum-free doublets are efficient and should be
evaluated in randomized phase III trials.
The triplet combinations are more toxic but not more
effective, and should not be used in practice.
The sequential protocols are more toxic but not more
effective and should be evaluated in randomized phase
III trials.
The role of targeted therapies in the management of
metastatic bladder TCC has not yet been defined.
Nevertheless, targeting angiogenesis seem to be very
promising.
(B) Second and third line treatments
For patients with platinum sensitive disease, a second
line treatment based on cisplatin should be used in
patient eligible to cisplatin. For cisplatin ineligible
patients, a regimens based on carboplatin can be used.
Vinflunine and gemcitabine-paclitaxel are 2 reasonable
therapeutic options in patients with cisplatin refractory
disease.
All active drugs can be used in second and third line
treatments.
6 - Conclusions
Chemotherapy plays a major role in the management of
bladder cancer [87,88]. In the metastatic setting, palliative
chemotherapy based on cisplatin type MVAC, HD-MVAC,
or GC or DD-GC remains the treatment of choice. In unfit
patients, Carboplatin based chemotherapy type Gemcita-
bin-Carboplatin or Methotrexate-Carboplatin-Vinblatine
(MCAVI) is a good option for these patients. Novel thera-
pies, targeting angiogenesis, have been shown to be very
promising. Therapeutic investigations should be continued
with the development of new drugs and targeted therapies
to improve treatment results in the metastatic bladder
cancer.
Abbreviations
AKT: Protein Kinase B; ASCO: American society of clinical oncology; AUC: air
under the curve; CaPG: carboplatin, Paclitaxel, and gemcitabine; CISCA:
cisplatin, cyclophosphamide, and doxorubicin; C-Kit: Stem Cell Factor; CMV:
cisplatin, methotrexate, and vinblastine; CR: complete response; DC:
docetaxel plus cisplatin; DD-GC: dose dense GC; EDC: epirubicin, docetaxel,
and cisplatin; EGFR: epidermal growth factor receptor; EORT: European
organization of research and treatment; FDA: food and drug administration;
FGFR: fibroblast growth factor receptor; GC: gemcitabine plus cisplatin; GCa:
gemcitabine plus carboplatin; GCSF: granulocyte colony stimulating factor;
GIST: gastrointestinal stromal tumor; HER2: human epidermal growth factor
receptor 2; ITCa: ifosfamide, paclitaxel, and carboplatin; ITP: ifosfamide,
paclitaxel, and cisplatin; MCAVI: methotrexate, carboplatin, and vinblastine;
M-GP: methotrexate, gemcitabine, paclitaxel; mTOR: mammalian target of
Table 7 Treatment recommendations:
First line treatment Second and third line treatments
Patients eligible to cisplatin Unfit
patients
Cisplatin sensitive disease Cisplatin refractory disease
MVAC, HD-MVAC, GC, and
DD-GC
GCa and
MCAVI
Cisplatin based doublet not used in first
line
Vinflunine, Paclitaxel-Gemcitabine, and all actives drugs
not used
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Page 8 of 11rapamycin; MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin; HD-
MVAC: high dose MVAC; ORR: overall response rate; OS: overall survival; PCa:
paclitaxel plus carboplatin; PCG: paclitaxel, cisplatin, and gemcitabine;
PDGFR: platelet derived growth factor; PFS: progression free survival; PI3K:
phosphoinositide 3-kinases; PR: partial response; RAF: human proto-
oncogene serine/threonine-protein kinase; S: stabilization; TCC: transitional
cell carcinoma; TTP: time to progression VEGFR: vascular endothelial growth
factor receptor
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